tiprankstipranks
Vertex Pharmaceuticals (MX:VRTX)
:VRTX
Mexico Market
EarningsQ2 2026 Earnings Report

Vertex Pharmaceuticals (VRTX) Q2 2026 Earnings Report

0 Followers

MX:VRTX Q2 2026 EPS Results

Actual EPS$80.27
Consensus EPS$80.46
Beat/MissMissed by -$0.19
One Year Ago EPS$76.71

MX:VRTX Q2 2026 Revenue Results

Actual Revenue$56.75B
Expected Revenue$54.82B
Beat/MissBeat by +$1.93B
YoY Revenue Growth+11.99%

Earnings Announcement Details

QuarterQ2 2026
Date08/03/2026
TimeAfter Close
Conference CallMonday, August 3, 2026
MX:VRTX Upcoming Earnings
Vertex Pharmaceuticals's next earnings date is estimated for November 9, 2026, based on past reporting schedules.

Q2 2026 Earnings Call Audio

MX:VRTX Q2 2026 Earnings Call
0:00 / 0:00

Q2 2026 Earnings Slide Deck

Q2 2026 Earnings Call Summary

Q2 2026
Earnings Call Date:Aug 03, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call presented a largely positive commercial and clinical update: revenue and key product launches (ALYFTREK, CASGEVY, JOURNAVX) showed strong momentum, guidance was raised, multiple clinical and regulatory milestones were achieved or on track (Pove BLA accepted, AMPLITUDE/AMPLIFIED/AGLOW enrollment complete or progressing, VX‑017 IND cleared), and the Crinetics acquisition adds a new specialty pillar. Offsetting factors include higher SG&A and upcoming operating expense at the high end of guidance, gross margin pressure from product mix and manufacturing investments, short‑term revenue volatility for cell therapies and PSP‑driven gross‑to‑net impacts (normalization expected in H1 2027), and near‑term costs and debt associated with the Crinetics deal. Overall, the positive commercial execution and pipeline progress outweigh the near‑term cost and execution risks.
Company Guidance
Vertex raised full‑year 2026 revenue guidance to $13.1–$13.2 billion while reiterating expectations for at least $500 million of non‑CF revenue and a roughly 150 basis‑point net benefit from foreign exchange; full‑year gross margin is expected to be just under 86% and combined non‑GAAP operating expenses are guided to $5.65–$5.75 billion (with management expecting to be at the high end). They expect a non‑GAAP effective tax rate of 19.5%–20.5% for 2026 (YTD at 20.4%), noted that the pending Crinetics acquisition (~$8.8 billion net of cash, to be funded with cash plus a $4.5 billion term loan) is expected to close in Q3 with modest 2026 P&L impact and to be accretive to non‑GAAP operating income in 2029, and said they will update 2026 guidance at close. Quarterly metrics highlighted alongside guidance included Q2 revenue of $3.3 billion (+12% YoY, with ~170 bps FX benefit), Q2 gross margin of 85.6%, Q2 non‑GAAP EPS of $4.73 (+5% YoY), Q2 non‑GAAP R&D of $889 million and SG&A of $520 million, cash and investments of ~$13.6 billion, and Q2 share repurchases of ~$455 million (~1 million shares).
Total Revenue Growth
Q2 2026 total revenue of $3.3 billion, up 12% year‑over‑year; company raised full‑year 2026 revenue guidance to $13.1–$13.2 billion.
Cystic Fibrosis Strength
Global CF revenue grew 11% year‑over‑year with ALYFTREK uptake a key driver; ALYFTREK exceeded $1 billion in revenue in H1 2026 and clinical data show ~2/3 of children <12 and >75% of patients ≥12 achieved sweat chloride <30 mmol/L.
CASGEVY Rapid Commercial Rollout
CASGEVY revenue of $76 million in Q2 2026, ~75% sequential growth versus Q1 2026 and over 150% year‑over‑year; received FDA supplemental approval for ages 2+ in 53 days and first pediatric patient initiated.
JOURNAVX Launch Momentum
JOURNAVX revenue of $50 million in Q2 2026 (vs $12M in Q2 2025); sequential revenue growth ~70% and sequential prescription growth ~45% vs Q1 2026; Q2 prescriptions ~535,000 and ~900,000 YTD; coverage now ~260M lives (180M unrestricted).
Renal Pipeline & Regulatory Progress
BLA for povetacicept (Pove) in IgAN accepted by FDA with November 30 PDUFA; RAINIER Phase III interim analysis described as statistically significant across primary and secondary endpoints; OLYMPUS Phase II/III in membranous nephropathy advanced to Phase III with 80 mg q4w dose selected by IDMC.
Clinical Pipeline Momentum
Completed enrollment in AGLOW (VX‑407 in ADPKD); AMPLITUDE (inaxaplin in AMKD) tracking to complete enrollment by year‑end with interim analysis results expected early 2027; AMPLIFIED completed enrollment with results expected this fall; VX‑828 cohort dosing completed with data expected H2 2026.
Type 1 Diabetes Progress
Zimislecel dosing resumed after manufacturing review and IND cleared for VX‑017 (Type O universal donor), potentially doubling addressable market from ~60,000 to ~120,000 patients and shortening time differential vs zimislecel.
Strong Financial Position & Capital Return
Cash and investments of approximately $13.6 billion at quarter end; repurchased ~1 million shares for ~$455 million during Q2 2026.
Guidance & FX Tailwinds
Full‑year 2026 revenue outlook raised; Q2 benefited from ~170 basis points of FX tailwind and management expects ~150 basis points FX benefit for full year 2026 (net of hedging).
Strategic Acquisition to Add New Pillar
Definitive agreement to acquire Crinetics Pharmaceuticals to add rare endocrine diseases as a fifth commercial pillar; transaction ~$8.8 billion net of cash, expected close in Q3 2026 and accretive to non‑GAAP operating income by 2029.

MX:VRTX Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Nov 09, 2026
2026 (Q3)
80.96 / -
81.457
2026 (Q2)
80.46 / 80.27
76.7054.65% (+3.56)
2026 (Q1)
72.00 / 75.86
68.89910.10% (+6.96)
2025 (Q4)
86.73 / 85.36
67.54126.38% (+17.82)
2025 (Q3)
77.60 / 81.46
74.3299.59% (+7.13)
2025 (Q2)
72.77 / 76.71
-217.727135.23% (+294.43)
2025 (Q1)
73.26 / 68.90
80.778-14.71% (-11.88)
2024 (Q4)
68.15 / 67.54
71.275-5.24% (-3.73)
2024 (Q3)
69.20 / 74.33
69.2387.35% (+5.09)
2024 (Q2)
-197.29 / -217.73
66.014-429.82% (-283.74)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed